Several months after forging a fresh path forward for its troubled Friedreich ataxia (FA) drug vatiquinone, PTC Therapeutics ...

Additionally, PTC analyzed long-term open-label data from an earlier study of vatiquinone in adults with FA. Following 24-months of treatment with vatiquinone, subjects had a 4.8-point benefit on the ...

Larimar Therapeutics' CTI-1601 offers hope for Friedreich's ataxia patients, with promising trial results. Check out why LRMR ...

A Friedreich ataxia specialist discusses how the typical clinical presentation of Friedreich's Ataxia includes early onset with symptoms such as ataxia and sensory loss, while also examining the ...

Panelists discuss how the differential diagnosis for Friedreich's Ataxia involves distinguishing it from other ataxias, the ...

In order to improve the quality of life of patients with the Ataxia disease, the biotechnological and pharmaceutical industry ...

A significant minority of patients with brain metastases may avoid radiotherapy, but they need to be carefully selected.

Research led by scientists at Queen Mary University of London is heralding in a new era for genetic sequencing and testing.

Most people haven’t heard of the condition, but Friedreich’s ataxia is getting more attention because of a new treatment and ...

Repare Therapeutics said it received encouraging early phase 1 data for its camonsertib inhibitor combined with palliative radiation for the treatment of metastatic tumors harboring an ...

The biotech sector was in focus last week, with regular pipeline and regulatory updates. Drug approvals were in the spotlight ...

Bill Nye, who has helped make science a part of pop culture for a generation of adults and children, is now using his ...